Progress toward therapy with antisense-mediated splicing modulation

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 2, 2009, Pages 116-123

  Du, Liutao ^a   Gatti, Richard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative splicing; Antisense oligonucleotide; Cancer; Genetic disorder; Molecular therapy; Splicing modulation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; CELL PENETRATING PEPTIDE; DIOCTADECYLDIMETHYLAMMONIUM CHLORIDE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DYSTROPHIN; LIPID; LIPOSOME; LOCKED NUCLEIC ACID; M 918; MESSENGER RNA PRECURSOR; METHYLMALONYL COENZYME A MUTASE; MYOTONIC DYSTROPHY PROTEIN KINASE; NANOCARRIER; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PENETRATIN; PEP 3; PEPTIDE NUCLEIC ACID; PHOSPHOROAMIDATE MORPHOLINO OLIGOMER; PRO 051; PROPIONYL COENZYME A CARBOXYLASE; SMALL INTERFERING RNA; SMALL NUCLEAR RNA; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTISENSE THERAPY; ATAXIA TELANGIECTASIA; BINDING SITE; BREAST CANCER; CANCER CELL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; KNOCKOUT GENE; METHYLMALONIC ACIDEMIA; MOLECULAR THERAPY; MUSCLE BIOPSY; MYOTONIC DYSTROPHY; NONHUMAN; POINT MUTATION; PROPIONIC ACIDEMIA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RNA SPLICING; RNA TRANSCRIPTION; SINGLE DRUG DOSE; SPINAL MUSCULAR ATROPHY; TIBIALIS ANTERIOR MUSCLE; VIRUS ENCEPHALITIS; ZINC FINGER MOTIF;

ALTERNATIVE SPLICING; GENETIC DISEASES, INBORN; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING;

EID: 63849152847     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Chan JH, Lim S, Wong ong WS: Antisense oligonucleotides: From design to therapeutic application. Clin Exp Pharmacol Physiol (2006) 33(5-6):533-540.
2. Morcos PA: Achieving targeted and quantifiable alteration of mRNA splicing with morpholino oligos. Biochem Biophys Res Commun (2007) 358(2):521-527.
3. Pande V, Nilsson L: Insights into structure, dynamics and hydration of locked nucleic acid (LNA) strand-based duplexes from molecular dynamics simulations. Nucleic Acids Res (2008) 36(5):1508-1516.
4. Amantana A, Iversen PL: Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol (2005) 5(5):550-555.
5. Lundin KE, Good L, Stromberg R, Graslund A, Smith CI: Biological activity and biotechnological aspects of peptide nucleic acid. Adv Genet (2006) 56:1-51.
6. Sazani P, Kole R: Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest (2003) 112(4):481-486.
7. Scaffidi P, Misteli T: Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med (2005) 11(4):440-445.
8. Vetrini F, Tammaro R, Bondanza S, Surace EM, Auricchio A, De LM, Ballabio A, Marigo V: Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides. Hum Mutat (2006) 27(5):420-426.
9. Artsma-Rus A, van Ommen GJ: Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA (2007) 13(10):1609-1624.
10. Garcia-Blanco MA, Baraniak AP, Lasda EL: Alternative splicing in disease and therapy. Nat Biotechnol (2004) 22(5):535-546.
11. Vickers TA, Zhang H, Graham MJ, Lemonidis KM, Zhao C, Dean NM: Modification of MyD88 mRNA splicing and inhibition of IL-1β signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide. J Immunol (2006) 176(6):3652-3661.
12. Lefebvre S, B̈rglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 80(1):155-165.
13. Monani UR: Spinal muscular atrophy: A deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron (2005) 48(6):885-896.
14. Lim SR, Hertel KJ: Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing. J Biol Chem (2001) 276(48):45476-45483.
15. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA (2003) 100(7):4114-4119.
16. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR: Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol (2007) 5(4):e73.
17. Kashima T, Rao N, Manley JL: An intronic element contributes to splicing repression in spinal muscular atrophy. Proc Natl Acad Sci USA (2007) 104(9):3426-3431.
18. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR: Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet (2008) 82(4):834-848.
19. Buratti E, Stuani C, De PG, Baralle FE: SR proteinmediated inhibition of CFTR exon 9 inclusion: Molecular characterization of the intronic splicing silencer. Nucleic Acids Res (2007) 35(13):4359-4368.
20. Artsma-Rus A, Janson AA, Heemskerk JA, De Winter CL, van Ommen GJ, van Deutekom JC: Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides. Ann NY Acad Sci (2006) 1082:74-76.
21. Goto M, Sawamura D, Nishie W, Sakai K, McMillan JR, Akiyama M, Shimizu H: Targeted skipping of a single exon harboring a premature termination codon mutation: Implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol (2006) 126(12):2614-2620.
22. Khoo B, Roca X, Chew SL, Krainer AR: Antisense oligonucleotide-induced alternative splicing of the apoB mRNA generates a novel isoform of apoB. BMC Mol Biol (2007) 8:3.
23. Artsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC: Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther (2006) 14(3):401-407.
24. Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S, Wilton SD: Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. BMC Mol Biol (2007) 8:57.
25. Xie SY, Ren ZR, Zhang JZ, Guo XB, Wang QX, Wang S, Lin D, Gong XL, Li W, Huang SZ, Zeng F, Zeng YT: Restoration of the balanced α/β-globin gene expression in β654-thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet (2007) 16(21):2616-2625.
26. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE: Nonsense-mediated decay approaches the clinic. Nat Genet (2004) 36(8):801-808.
27. Asparuhova MB, Marti G, Liu S, Serhan F, Trono D, Schumperli D: Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med (2007) 9(5):323-334.
28. Query CC, Moore MJ, Sharp PA: Branch nucleophile selection in pre-mRNA splicing: Evidence for the bulged duplex model. Genes Dev (1994) 8(5):587-597.
29. Cavaille J, Nicoloso M, Bachellerie JP: Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides. Nature (1996) 383(6602):732-735.
30. Zhao X, Yu YT: Targeted pre-mRNA modification for gene silencing and regulation. Nat Methods (2008) 5(1):95-100.
31. Gorman L, Suter D, Emerick V, Scḧmperli D, Kole R: Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA (1998) 95(9):4929-4934.
32. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ: Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther (2005) 12(6):1013-1022.
33. Gorman L, Suter D, Emerick V, Schumperli D, Kole R: Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA (1998) 95(9):4929-4934.
34. Denti MA, Rosa A, D'Antona G, Sthandier O, De Angelis FG, Nicoletti C, Allocca M, Pansarasa O, Parente V, Musaro A, Auricchio A, Bottinelli R, Bozzoni I: Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice. Hum Gene Ther (2006) 17(5):565-574.
35. Uchikawa H, Fujii K, Kohno Y, Katsumata N, Nagao K, Yamada M, Miyashita T: U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites. J Hum Genet (2007) 52(11):891-897.
36. Marquis J, Meyer K, Angehrn L, Kampfer SS, Rothen-Rutishauser B, Schumperli D: Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol Ther (2007) 15(8):1479-1486.
37. Taylor JK, Zhang QQ, Wyatt JR, Dean NM: Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol (1999) 17(11):1097-1100.
38. runo IG, Jin W, Cote GJ: Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet (2004) 13(20):2409-2420.
39. Teraoka SN, Telatar M, Becker-Catania S, Liang T, Oneng̈t S, Tolun A, Chessa L, Sanal O, Bernatowska E, Gatti RA, Concannon P: Splicing defects in the ataxia-telangiectasia gene, ATM: Underlying mutations and consequences. Am J Hum Genet (1999) 64(6):1617-1631.
40. Du L, Pollard JM, Gatti RA: Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci USA (2007) 104(14):6007- 6012.
41. Ugarte M, Aguado C, Desviat LR, Sanchez-Alcudia R, Rincon A, Perez B: Propionic and methylmalonic acidemia: Antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet (2007) 81(6):1262-1270.
42. Cooper TA: A reversal of misfortune for myotonic dystrophy? N Engl J Med (2006) 355(17):1825-1827.
43. Lueck JD, Mankodi A, Swanson MS, Thornton CA, Dirksen RT: Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol (2007) 129(1):79-94.
44. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA: Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 117(12):3952- 3957.
45. Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S: Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther (2007) 15(7):1288-1296.
46. Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD: The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther (2007) 15(1):157-166.
47. Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB, Weiss RB, Wilton SD, Flanigan KM: DMD pseudoexon mutations: Splicing efficiency, phenotype, and potential therapy. Ann Neurol (2008) 63(1):81-89.
48. McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD: Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord (2006) 16(9-10): 583-590.
49. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ et al: Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 357(26):2677-2686.
50. Hoffman EP: Skipping toward personalized molecular medicine. N Engl J Med (2007) 357(26):2719-2722.
51. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M: Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res (2006) 59(5):690-694.
52. Foged C, Nielsen HM: Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv (2008) 5(1):105-117.
53. Resina S, Abes S, Turner JJ, Prevot P, Travo A, Clair P, Gait MJ, Thierry AR, Lebleu B: Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int J Pharm (2007) 344(1-2):96-102.
54. Morris MC, Gros E, Aldrian-Herrada G, Choob M, Archdeacon J, Heitz F, Divita G: A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res (2007) 35(7):e49.
55. El-Andaloussi S, Johansson HJ, Holm T, Langel U: A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther (2007) 15(10): 1820-1826.
56. 4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release (2006) 116(3):304-313.
57. Abes S, Turner JJ, Ivanova GD, Owen D, Williams D, Arzumanov A, Clair P, Gait MJ, Lebleu B: Efficient splicing correction by PNA conjugation to an R6-penetratin delivery peptide. Nucleic Acids Res (2007) 35(13):4495-4502.
58. Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, Mourich DV: Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods (2007) 325(1-2):114-126.
59. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD: Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther (2007) 15(9):1587-1592.
60. Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS, Iversen PL: Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem (2007) 18(4):1325-1331.
61. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N: Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 448(7149):39-43.
62. Lv H, Zhang S, Wang B, Cui S, Yan J: Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 114(1):100-109.
63. Sokolova V, Epple M: Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl (2008) 47(8):1382- 1395.
64. Fenske DB, Cullis PR: Liposomal nanomedicines. Expert Opin Drug Deliv (2008) 5(1):25-44.
65. Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH: Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res (2007) 67(7):2938-2943.
66. Eom KD, Park SM, Tran HD, Kim MS, Yu RN, Yoo H: Dendritic α,ε-poly(l-lysine)s as delivery agents for antisense oligonucleotides. Pharm Res (2007) 24(8):1581-1589.
67. Seferos DS, Giljohann DA, Rosi NL, Mirkin CA: Locked nucleic acid-nanoparticle conjugates. Chembiochem (2007) 8(11):1230- 1232.
68. Wang Y, Nakamura K, Liu X, Kitamura N, Kubo A, natowich DJ: Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture. Bioconjug Chem (2007) 18(4):1338-1343.
69. Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet (2002) 30(1):13-19.
70. Caceres JF, Kornblihtt AR: Alternative splicing: Multiple control mechanisms and involvement in human disease. Trends Genet (2002) 18(4):186-193.
71. Srebrow A, Kornblihtt AR: The connection between splicing and cancer. J Cell Sci (2006) 119(Pt 13):2635-2641.
72. Wojciechowski F, Hudson RH: Nucleobase modifications in peptide nucleic acids. Curr Top Med Chem (2007) 7(7):667-679.
73. Pensato S, Saviano M, Romanelli A: New peptide nucleic acid analogues: Synthesis and applications. Expert Opin Biol Ther (2007) 7(8):1219-1232.
74. Shiraishi T, Hamzavi R, Nielsen PE: Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells. Nucleic Acids Res (2008) 36(13):4424-4432.